LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 213

Search options

  1. Book ; Online ; E-Book: Treatment-Resistant Depression

    Li, Cheng-Ta / Zheng, Zhiming

    (Issn Series)

    2023  

    Author's details Cheng-Ta Li and Chih-Ming Cheng
    Series title Issn Series
    Keywords Depression, Mental/Treatment
    Subject code 616.852706
    Language English
    Size 1 online resource (190 pages)
    Edition First edition.
    Publisher Zoe Kruze
    Publishing place Cambridge, MA
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 0-323-95778-1 ; 0-323-95779-X ; 978-0-323-95778-6 ; 978-0-323-95779-3
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book ; Online ; E-Book: Treatment-Resistant Depression Part B

    Zheng, Zhiming / Li, Cheng-Ta

    2023  

    Author's details Chih-Ming Cheng and Cheng-Ta Li
    Keywords Depression/Mental Treatment
    Subject code 733
    Language English
    Size 1 online resource (190 pages)
    Edition First edition.
    Publisher Elsevier
    Publishing place Amsterdam, Netherlands
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 0-443-22395-5 ; 0-443-22394-7 ; 978-0-443-22395-2 ; 978-0-443-22394-5
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  3. Article ; Online: Preface.

    Li, Cheng-Ta

    Progress in brain research

    2023  Volume 278, Page(s) xi

    Language English
    Publishing date 2023-06-05
    Publishing country Netherlands
    Document type Editorial
    ISSN 1875-7855 ; 0079-6123
    ISSN (online) 1875-7855
    ISSN 0079-6123
    DOI 10.1016/S0079-6123(23)00065-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Overview of treatment-resistant depression.

    Li, Cheng-Ta

    Progress in brain research

    2023  Volume 278, Page(s) 1–23

    Abstract: Patients with major depressive disorder (MDD) often exhibit an inadequate treatment response or failure to achieve remission following treatment with antidepressant drugs. Treatment-resistant depression (TRD) is proposed to identify this clinical ... ...

    Abstract Patients with major depressive disorder (MDD) often exhibit an inadequate treatment response or failure to achieve remission following treatment with antidepressant drugs. Treatment-resistant depression (TRD) is proposed to identify this clinical scenario. Compared to those without TRD, patients with TRD have significantly lower health-related quality of life in mental and physical dimensions, more functional impairment and productivity loss, and higher healthcare costs. TRD imposes a massive burden on the individual, family, and society. However, a lack of consensus on the TRD definition limits the comparison and interpretation of TRD treatment efficacy across trials. Furthermore, because of the various TRD definitions, there is scarce treatment guideline specifically for TRD, in contrast to the rich treatment guidelines for MDD. In this chapter, common issues related to TRD, such as proper definitions of an adequate antidepressant trial and TRD, were carefully reviewed. Prevalence of and clinical outcomes related to TRD were summarized. We also summarized the staging models ever proposed for the diagnosis of TRD. Furthermore, we highlighted variations in the definition regarding the lack of or an inadequate response in treatment guidelines for depression. Up-to-date treatment options for TRD, including pharmacological strategies, psychotherapeutic interventions, neurostimulation techniques, glutamatergic compounds, and even experimental agents were reviewed.
    MeSH term(s) Humans ; Antidepressive Agents/therapeutic use ; Depression ; Depressive Disorder, Major/drug therapy ; Depressive Disorder, Treatment-Resistant/drug therapy ; Depressive Disorder, Treatment-Resistant/diagnosis ; Quality of Life
    Chemical Substances Antidepressive Agents
    Language English
    Publishing date 2023-05-15
    Publishing country Netherlands
    Document type Comparative Study ; Journal Article
    ISSN 1875-7855 ; 0079-6123
    ISSN (online) 1875-7855
    ISSN 0079-6123
    DOI 10.1016/bs.pbr.2023.03.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Preface.

    Li, Cheng-Ta

    Progress in brain research

    2023  Volume 281, Page(s) xiii

    Language English
    Publishing date 2023-08-07
    Publishing country Netherlands
    Document type Editorial
    ISSN 1875-7855 ; 0079-6123
    ISSN (online) 1875-7855
    ISSN 0079-6123
    DOI 10.1016/S0079-6123(23)00104-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: A review of critical brain oscillations in depression and the efficacy of transcranial magnetic stimulation treatment.

    Tsai, Yi-Chun / Li, Cheng-Ta / Juan, Chi-Hung

    Frontiers in psychiatry

    2023  Volume 14, Page(s) 1073984

    Abstract: Repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS) have been proven effective non-invasive treatments for patients with drug-resistant major depressive disorder (MDD). However, some depressed patients do ... ...

    Abstract Repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS) have been proven effective non-invasive treatments for patients with drug-resistant major depressive disorder (MDD). However, some depressed patients do not respond to these treatments. Therefore, the investigation of reliable and valid brain oscillations as potential indices for facilitating the precision of diagnosis and treatment protocols has become a critical issue. The current review focuses on brain oscillations that, mostly based on EEG power analysis and connectivity, distinguish between MDD and controls, responders and non-responders, and potential depression severity indices, prognostic indicators, and potential biomarkers for rTMS or iTBS treatment. The possible roles of each biomarker and the potential reasons for heterogeneous results are discussed, and the directions of future studies are proposed.
    Language English
    Publishing date 2023-05-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2564218-2
    ISSN 1664-0640
    ISSN 1664-0640
    DOI 10.3389/fpsyt.2023.1073984
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Repetitive Transcranial Magnetic Stimulation-Related Seizure in a Patient Treated With Olanzapine.

    Chen, Yu-Chen / Cheng, Chih-Ming / Li, Cheng-Ta

    American journal of therapeutics

    2022  Volume 31, Issue 1, Page(s) e70–e72

    MeSH term(s) Humans ; Olanzapine/adverse effects ; Seizures/etiology ; Transcranial Magnetic Stimulation ; Female ; Young Adult ; Depression/drug therapy
    Chemical Substances Olanzapine (N7U69T4SZR)
    Language English
    Publishing date 2022-05-27
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1280786-2
    ISSN 1536-3686 ; 1075-2765
    ISSN (online) 1536-3686
    ISSN 1075-2765
    DOI 10.1097/MJT.0000000000001518
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Current Updates on Newer Forms of Transcranial Magnetic Stimulation in Major Depression.

    Cheng, Chih-Ming / Li, Cheng-Ta / Tsai, Shih-Jen

    Advances in experimental medicine and biology

    2021  Volume 1305, Page(s) 333–349

    Abstract: Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved technique for treating medication-resistant depression. Conventional rTMS includes high frequency (HF) to left dorsolateral prefrontal cortex (DLPFC) and low frequency to right DLPFC. ...

    Abstract Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved technique for treating medication-resistant depression. Conventional rTMS includes high frequency (HF) to left dorsolateral prefrontal cortex (DLPFC) and low frequency to right DLPFC. However, not all depressed patients could benefit from standard rTMS protocols. Meta-analytical evidence indicated that there was an average response rate of 29.3% for patients receiving the most commonly adopted HF rTMS to the left DLPFC. Hence, newer forms of rTMS paradigms are warranted to improve antidepressant response and remission rate in patients with depression, especially those who are refractory to adequate antidepressant trials. In the current chapter, we review newer forms of rTMS paradigms and the content will cover standard theta burst stimulation (TBS), prolonged iTBS (piTBS), accelerated rTMS (aTMS), deep TMS (dTMS), priming TMS (pTMS), synchronized TMS (sTMS), and magnetic seizure therapy (MST).
    MeSH term(s) Antidepressive Agents/therapeutic use ; Depression ; Depressive Disorder, Major/drug therapy ; Humans ; Prefrontal Cortex ; Transcranial Magnetic Stimulation ; Treatment Outcome
    Chemical Substances Antidepressive Agents
    Language English
    Publishing date 2021-04-08
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Review
    ISSN 2214-8019 ; 0065-2598
    ISSN (online) 2214-8019
    ISSN 0065-2598
    DOI 10.1007/978-981-33-6044-0_18
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Reply: High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression.

    Li, Cheng-Ta / Su, Tung-Ping

    Brain : a journal of neurology

    2018  Volume 141, Issue 3, Page(s) e19

    MeSH term(s) Antidepressive Agents ; Depressive Disorder, Treatment-Resistant ; Humans ; Theta Rhythm ; Transcranial Magnetic Stimulation
    Chemical Substances Antidepressive Agents
    Language English
    Publishing date 2018-02-07
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awy013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation.

    Chen, Mu-Hong / Lin, Wei-Chen / Li, Cheng-Ta / Wu, Hui-Ju / Bai, Ya-Mei / Tsai, Shih-Jen / Su, Tung-Ping / Tu, Pei-Chi

    Journal of psychiatric research

    2023  Volume 165, Page(s) 91–95

    Abstract: Background: Evidence indicates that vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) influence the pathophysiology of depression. However, whether low-dose ketamine regulates VEGF and MMP-9 levels and whether changes in ... ...

    Abstract Background: Evidence indicates that vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) influence the pathophysiology of depression. However, whether low-dose ketamine regulates VEGF and MMP-9 levels and whether changes in VEGF and MMP-9 levels are associated with the antidepressant and antisuicidal effects of ketamine remained unclear.
    Methods: Forty-eight patients with treatment-resistant depression and strong suicidal ideation (TRD-SI) were randomly assigned to a single infusion of 0.5-mg/kg ketamine or 0.045-mg/kg midazolam. The Montgomery-Åsberg Depression Rating Scale (MADRS) and Columbia-Suicide Severity Rating Scale-Ideation Severity Subscale (CSSRS-ISS) were used at baseline and subsequently at several postinfusion timepoints. VEGF and MMP-9 serum levels were analyzed at baseline and on day 3 postinfusion.
    Results: After adjustment for baseline levels, no significant differences in VEGF (p = .912) and MMP-9 (p = .758) levels were identified on day 3 postinfusion between the study groups. Baseline VEGF levels but not MMP-9 levels were negatively associated with MADRS and CSSRS-ISS scores following infusion.
    Discussion: A single infusion of low-dose ketamine did not alter the VEGF and MMP-9 levels of the patients with TRD-SI. Higher baseline VEGF levels were associated with greater antidepressant and antisuicidal effects of single low-dose ketamine infusion.
    MeSH term(s) Humans ; Ketamine/pharmacology ; Ketamine/therapeutic use ; Suicidal Ideation ; Vascular Endothelial Growth Factor A/therapeutic use ; Depression ; Matrix Metalloproteinase 9/therapeutic use ; Treatment Outcome ; Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Depressive Disorder, Treatment-Resistant/drug therapy
    Chemical Substances Ketamine (690G0D6V8H) ; Vascular Endothelial Growth Factor A ; Matrix Metalloproteinase 9 (EC 3.4.24.35) ; Antidepressive Agents
    Language English
    Publishing date 2023-07-19
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3148-3
    ISSN 1879-1379 ; 0022-3956
    ISSN (online) 1879-1379
    ISSN 0022-3956
    DOI 10.1016/j.jpsychires.2023.07.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top